Company profile for EvolveImmune Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Bold Science. Better Outcomes. At EvolveImmune, we harness our “Immunology First” approach to create first-in-category cancer medicines to transform the lives of patients by delivering superior, long-term outcomes compared to current anti-cancer therapies. We are pioneers who rapidly translate discoveries into innovations and innovations into differentiated therapeutic solutions, to address the most significant unme...
Bold Science. Better Outcomes. At EvolveImmune, we harness our “Immunology First” approach to create first-in-category cancer medicines to transform the lives of patients by delivering superior, long-term outcomes compared to current anti-cancer therapies. We are pioneers who rapidly translate discoveries into innovations and innovations into differentiated therapeutic solutions, to address the most significant unmet medical needs in oncology.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
23 Business Park Drive Branford, CT 06405
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/08/14/3133320/0/en/EvolveImmune-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-EVOLVE104-a-Novel-Trispecific-T-Cell-Engager-with-Integrated-CD2-Costimulation.html

GLOBENEWSWIRE
14 Aug 2025

https://www.globenewswire.com/news-release/2025/04/08/3057460/0/en/EvolveImmune-Therapeutics-Announces-Translational-Research-Collaboration-to-Evaluate-Expression-of-Novel-Tumor-Target-in-Muscle-Invasive-Bladder-Cancer.html

GLOBENEWSWIRE
08 Apr 2025

https://www.globenewswire.com/news-release/2025/02/11/3024112/0/en/EvolveImmune-Appoints-Kristen-M-Hege-M-D-to-Its-Board-of-Directors.html

GLOBENEWSWIRE
11 Feb 2025

https://www.globenewswire.com/news-release/2024/11/11/2978201/0/en/EvolveImmune-Therapeutics-Presents-New-Preclinical-and-Translational-Data-Highlighting-Pipeline-Progress-for-EVOLVE-T-Cell-Engager-Platform-at-39th-Annual-Meeting-of-the-Society-fo.html

GLOBENEWSWIRE
11 Nov 2024

https://www.globenewswire.com/news-release/2024/10/31/2972538/0/en/AbbVie-and-EvolveImmune-Therapeutics-Announce-Collaboration-and-Option-to-License-Agreement-to-Develop-Next-Generation-Cancer-Biotherapeutics.html

GLOBENEWSWIRE
31 Oct 2024

https://www.globenewswire.com/news-release/2024/10/23/2967624/0/en/EvolveImmune-Therapeutics-to-Present-New-Preclinical-Data-Highlighting-Pipeline-Progress-for-EVOLVE-T-Cell-Engager-Platform-at-39th-Annual-Meeting-of-the-Society-for-Immunotherapy-.html

GLOBENEWSWIRE
23 Oct 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty